Physician

Daniel M Ibach, MD

According to 2025 Medicare claims, Daniel Ibach, MD (NPI: 1619947876) practices hematology/oncology in the Knoxville, TN market, with the plurality of this provider's patient population coming from Knox, TN. This provider's primary affiliated billing organization is TENNESSEE CANCER SPECIALISTS PLLC (NPI: 1841228871; TIN: 200677400) and primary practice location at 37932-3366. Ibach is affiliated with the Main Street Rural Health Cedar ACO LLC (ACO ID: A5502), participating under the MSSP model.

Ibach's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,214 traditional Medicare patients, billed 398,990 HCPCS/CPT codes, and received $8,457,368 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,869 prescription claims across 366 beneficiaries totaling $6,539,058 in drug costs, led by Revlimid (Lenalidomide). DME data shows 49 claims. Open Payments data shows 221 records totaling $4,668. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $139,207 to $8,457,368. Similarly, Part D prescription costs have moved sharply higher in recent years, from $701,671 to $6,539,058. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $3,825 and ending at $2,323.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	546	5,457	$139,207
2016	544	194,336	$2,708,989
2017	601	311,252	$3,823,650
2018	760	383,653	$6,045,380
2019	704	399,736	$6,783,109
2020	653	384,747	$7,643,785
2021	789	413,486	$6,737,488
2022	1,102	465,431	$7,456,578
2023	1,160	410,554	$7,511,471
2024	1,214	398,990	$8,457,368

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	270	1,650	$701,671
2016	254	1,438	$1,151,945
2017	255	1,576	$1,425,056
2018	318	1,770	$2,160,685
2019	317	1,798	$2,260,870
2020	315	1,753	$2,873,043
2021	352	1,937	$3,408,247
2022	372	1,968	$4,765,819
2023	378	1,913	$5,786,087
2024	366	1,869	$6,539,058

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	55	$3,269
2016	13	57	$3,494
2017	N/R	53	$1,764
2018	N/R	81	$12,191
2019	N/R	70	$8,762
2020	N/R	61	$5,544
2021	N/R	35	$2,734
2022	N/R	24	$2,204
2023	N/R	51	$4,625
2024	N/R	49	$3,194

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	777	1,670	$86
80053	Blood test, comprehensive group of blood chemicals	949	3,178	$10
36415	Insertion of needle into vein for collection of blood sample	931	3,111	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	971	3,657	$8
83615	Lactate dehydrogenase (enzyme) level	753	2,018	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	63	1,659	$1,038,267
Pomalyst	Pomalidomide	36	1,008	$800,489
Imbruvica	Ibrutinib	50	1,434	$701,706
Lenalidomide	Lenalidomide	61	1,484	$684,833
Kisqali	Ribociclib Succinate	43	1,204	$595,399

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4035	Enteral feeding supply kit; pump fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape	N	N/R	12	$1,823
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$765
A4394	Ostomy deodorant, with or without lubricant, for use in ostomy pouch, per fluid ounce	N	N/R	11	$400
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	221	$4,668	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel M. Ibach, MD?

Tedicare shows public-source Medicare data for Daniel M. Ibach, MD (NPI 1619947876), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel M. Ibach, MD have ACO affiliation data?

Daniel M. Ibach, MD is shown with ACO affiliation data for Main Street Rural Health Cedar ACO LLC (MSSP, ACO ID A5502).

What billing organization is linked to Daniel M. Ibach, MD?

Daniel M. Ibach, MD is linked to TENNESSEE CANCER SPECIALISTS PLLC (billing NPI 1841228871) in the available physician profile data.

Does Daniel M. Ibach, MD have Open Payments data?

Daniel M. Ibach, MD has 221 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.